精準基因組檢測市場 - 全球產業規模、佔有率、趨勢、機會和預測，按技術、按產品和服務（消耗品、設備、服務）、按應用、按最終用途、按地區和競爭進行細分，2020 年至 2030 年

2024 年全球精準基因組檢測市值為 155.1 億美元，預計到 2030 年將達到 209.8 億美元，預測期內的年複合成長率(CAGR) 為 5.12%。由於基因組定序技術的進步、個人化醫療的日益普及以及遺傳疾病和癌症發病率的上升，市場正在迅速擴大。精準基因組檢測包括分析個人的 DNA，以評估疾病易感性、提供治療決策依據以及根據基因圖譜客製化醫療干預措施。隨著全球醫療保健系統向精準醫療轉變，基因組檢測正在成為現代診斷和治療的基本組成部分。

次世代定序（NGS）在降低基因組檢測成本和提高效率方面發揮了關鍵作用，能夠快速定序整個基因組、外顯子組或目標基因組以進行全面的基因分析。這使得基因組檢測更容易用於臨床應用，例如癌症診斷、遺傳疾病篩檢和藥物基因組學。此外，Oxford Nanopore 和 PacBio 的 SMRT 定序等第三代定序 (TGS) 技術的發展進一步提高了 DNA 分析的準確性和效率。

主要市場促進因素

遺傳疾病和癌症發生率不斷上升

主要市場挑戰

成本高且可近性有限

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第4章：COVID-19 對全球精準基因組檢測市場的影響

第5章：全球精準基因組檢測市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依技術分類（次世代定序、聚合酶鍊式反應、微陣列技術、桑格定序、CRISPR/Cas 系統、其他）
  • 依產品及服務（耗材（試劑盒及試劑）、設備、服務）
  • 依應用分類（腫瘤學、心血管疾病、神經系統疾病、生殖健康、罕見疾病、其他）
  • 按最終用途醫院和診所、診斷實驗室、研究和學術機構、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美精準基因組檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第7章：歐洲精準基因組檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太精準基因組檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 韓國
  • 日本
  • 澳洲

第9章：南美洲精準基因組檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲精準基因組檢測市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如果有）
• 最新動態

第 13 章：全球精準基因組檢測市場：SWOT 分析

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 15 章：競爭格局

• Danaher Corporation
• Merck KGaA
• Revvity, Inc.
• Maravai LifeSciences Holdings Inc.
• GenScript Biotech
• QIAGEN NV
• PacBio Biosciences Inc.
• Oxford Nanopore Technologies plc.
• Illumina, Inc.
• 10x Genomics, Inc.

第 16 章：策略建議

第17章 關於出版商,免責事項

The Global Precision Genomic Testing Market was valued at USD 15.51 billion in 2024 and is projected to reach USD 20.98 billion by 2030, growing at a compound annual growth rate (CAGR) of 5.12% during the forecast period. The market is expanding rapidly due to advancements in genomic sequencing technologies, the increasing adoption of personalized medicine, and the rising prevalence of genetic disorders and cancers. Precision genomic testing involves analyzing an individual's DNA to assess disease predisposition, inform treatment decisions, and customize medical interventions based on genetic profiles. As healthcare systems globally shift toward precision medicine, genomic testing is becoming a fundamental component of modern diagnostics and therapeutics.

Next-generation sequencing (NGS) has played a key role in reducing the costs and enhancing the efficiency of genomic testing, enabling the rapid sequencing of entire genomes, exomes, or targeted gene panels for comprehensive genetic analysis. This has made genomic testing more accessible for clinical applications, such as cancer diagnostics, hereditary disease screening, and pharmacogenomics. Additionally, the development of third-generation sequencing (TGS) technologies, like Oxford Nanopore and PacBio's SMRT sequencing, has further improved the accuracy and efficiency of DNA analysis.

Key Market Drivers

Increasing Prevalence of Genetic Disorders and Cancer

The global precision genomic testing market is experiencing significant growth, driven by the increasing prevalence of genetic disorders and cancer worldwide. Precision genomic testing supports early detection, accurate diagnosis, and personalized treatment by analyzing an individual's genetic makeup. As demand for targeted therapies and precision medicine rises, the genomic testing market continues to expand, offering promising advancements in healthcare.

According to the CDC, when one parent carries an autosomal dominant disease, each child has a 50% chance of inheriting the associated genetic mutation. The rising prevalence of genetic disorders such as cystic fibrosis, sickle cell anemia, and Huntington's disease, largely due to greater awareness and improved diagnostic capabilities, is further driving market demand. Many inherited diseases require precise genetic analysis for proper diagnosis and management, making genomic testing a critical tool in modern medicine. Moreover, the growing use of whole genome sequencing and NGS technologies has enhanced the ability to identify genetic mutations linked to various hereditary conditions.

With approximately 10,000 distinct types of monogenic diseases-resulting from mutations in a single gene-that affect about 10 in every 1,000 people, the global prevalence of these diseases is estimated at 70 to 80 million individuals. Furthermore, cancer remains one of the leading causes of death worldwide, with millions of new cases diagnosed annually. Precision genomic testing plays a vital role in oncology by identifying genetic mutations that contribute to tumor formation.

Key Market Challenges

High Costs and Limited Accessibility

One of the primary challenges in the precision genomic testing market is the high cost associated with genomic sequencing and analysis. Advanced tests such as whole genome sequencing require sophisticated technologies, specialized expertise, and robust bioinformatics infrastructure, contributing to their high cost. Many healthcare systems, particularly in developing regions, face difficulties in integrating these services due to limited funding and the absence of reimbursement policies. Consequently, access to precision genomic testing remains restricted, limiting its broader adoption among patients who could benefit from early diagnosis and personalized treatment.

Key Market Players

• Danaher Corporation
• Merck KGaA
• Revvity, Inc.
• Maravai LifeSciences
• GenScript Biotech
• QIAGEN N.V.
• PacBio Biosciences Inc.
• Oxford Nanopore Technologies plc.
• Illumina, Inc.
• 10x Genomics, Inc.

Report Scope

This report segments the Global Precision Genomic Testing Market as follows, detailing the industry trends:

Market by Technology:

• Next-Generation Sequencing
• Polymerase Chain Reaction
• Microarray Technology
• Sanger Sequencing
• CRISPR/Cas Systems
• Others

Market by Product & Service:

• Consumables
• Equipment
• Services

Market by Application:

• Oncology
• Cardiovascular Diseases
• Neurological Disorders
• Reproductive Health
• Rare Diseases
• Others

Market by End Use:

• Hospitals and Clinics
• Diagnostic Laboratories
• Research & Academic Institutes
• Others

Market by Region:

• North America (United States, Canada, Mexico)
• Europe (France, United Kingdom, Italy, Germany, Spain)
• Asia Pacific (China, India, Japan, Australia, South Korea)
• South America (Brazil, Argentina, Colombia)
• Middle East & Africa (South Africa, Saudi Arabia, UAE)

Competitive Landscape

Company Profiles: A detailed analysis of the major players in the Global Precision Genomic Testing Market.

Available Customizations:

TechSci Research offers customization options for the Global Precision Genomic Testing Market report, tailored to meet a company's specific needs.

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Precision Genomic Testing Market

5. Global Precision Genomic Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarray Technology, Sanger Sequencing, CRISPR/Cas Systems, Others)
  • 5.2.2. By Product & Services (Consumables (Kits & Reagents), Equipment, Services)
  • 5.2.3. By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Rare Diseases, Others)
  • 5.2.4. By End-Use Hospitals and Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Precision Genomic Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Product & Services
  • 6.2.3. By Application
  • 6.2.4. By End Use
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Precision Genomic Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Product & Services
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End Use
  • 6.3.2. Mexico Precision Genomic Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Product & Services
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End Use
  • 6.3.3. Canada Precision Genomic Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Product & Services
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End Use

7. Europe Precision Genomic Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Product & Services
  • 7.2.3. By Application
  • 7.2.4. By End Use
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Precision Genomic Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Product & Services
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End Use
  • 7.3.2. Germany Precision Genomic Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Product & Services
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End Use
  • 7.3.3. United Kingdom Precision Genomic Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Product & Services
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End Use
  • 7.3.4. Italy Precision Genomic Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Product & Services
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End Use
  • 7.3.5. Spain Precision Genomic Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Product & Services
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End Use

8. Asia Pacific Precision Genomic Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Product & Services
  • 8.2.3. By Application
  • 8.2.4. By End Use
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Precision Genomic Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Product & Services
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End Use
  • 8.3.2. India Precision Genomic Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Product & Services
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End Use
  • 8.3.3. South Korea Precision Genomic Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Product & Services
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End Use
  • 8.3.4. Japan Precision Genomic Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Product & Services
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End Use
  • 8.3.5. Australia Precision Genomic Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Product & Services
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End Use

9. South America Precision Genomic Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Product & Services
  • 9.2.3. By Application
  • 9.2.4. By End Use
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Precision Genomic Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Product & Services
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End Use
  • 9.3.2. Argentina Precision Genomic Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Product & Services
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End Use
  • 9.3.3. Colombia Precision Genomic Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Product & Services
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End Use

10. Middle East and Africa Precision Genomic Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Product & Services
  • 10.2.3. By Application
  • 10.2.4. By End Use
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Precision Genomic Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Product & Services
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End Use
  • 10.3.2. Saudi Arabia Precision Genomic Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Product & Services
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End Use
  • 10.3.3. UAE Precision Genomic Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Product & Services
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Precision Genomic Testing Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Danaher Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Merck KGaA
• 15.3. Revvity, Inc.
• 15.4. Maravai LifeSciences Holdings Inc.
• 15.5. GenScript Biotech
• 15.6. QIAGEN N.V.
• 15.7. PacBio Biosciences Inc.
• 15.8. Oxford Nanopore Technologies plc.
• 15.9. Illumina, Inc.
• 15.10. 10x Genomics, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer